Literature DB >> 24960653

Splenectomy improves anaemia but does not reduce iron burden in patients with haemoglobin H Constant Spring disease.

Ya-Li Zhou1, Xin-Hua Zhang1, Tie-Niu Liu1, Li Wang1, Xiao-Lin Yin1.   

Abstract

BACKGROUND: Splenectomy is reported to increase the haemoglobin level in patients with haemoglobin H Constant Spring (HbH CS) disease; however, its impact on iron burden and the underlying mechanism remains unclear.
MATERIALS AND METHODS: From March through to May 2013, a total of 50 adults with HbH CS disease (25 cases splenectomised and 25 cases non-splenectomised) were enrolled. The patients' general conditions, history of blood transfusion and iron chelator treatment were investigated. Levels of haemoglobin, nucleated red blood cell counts, and serum ferritin were measured. The percentage of apoptotic erythroid precursor cells in bone marrow, an index representing ineffective erythropoiesis, was determined in some cases.
RESULTS: There were no significant differences in age, blood transfusion volume, and use of iron chelator drugs between the splenectomised group and the non-splenectomised group. Significantly higher haemoglobin levels, serum ferritin levels and nucleated red blood cell counts as well as a higher percentage of apoptotic erythroid progenitor cells were detected in the splenectomised group. Regression analysis revealed that age and nucleated red blood cell counts were independent risk factors affecting the serum ferritin level. DISCUSSION: Despite improving the haemoglobin level, splenectomy is associated with greater iron burden in HbH CS disease. A high nucleated red blood cell count is predictive of the risk of severe iron overload.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24960653      PMCID: PMC4212026          DOI: 10.2450/2014.0247-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  30 in total

1.  Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy.

Authors:  D A RIGAS; R D KOLER
Journal:  Blood       Date:  1961-07       Impact factor: 22.113

2.  The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening.

Authors:  X M Xu; Y Q Zhou; G X Luo; C Liao; M Zhou; P Y Chen; J P Lu; S Q Jia; G F Xiao; X Shen; J Li; H P Chen; Y Y Xia; Y X Wen; Q H Mo; W D Li; Y Y Li; L W Zhuo; Z Q Wang; Y J Chen; C H Qin; M Zhong
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

3.  Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Authors:  Sara Gardenghi; Maria F Marongiu; Pedro Ramos; Ella Guy; Laura Breda; Amy Chadburn; YiFang Liu; Ninette Amariglio; Gideon Rechavi; Eliezer A Rachmilewitz; William Breuer; Z Ioav Cabantchik; Diedra M Wrighting; Nancy C Andrews; Maria de Sousa; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

4.  Clinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypes.

Authors:  R Origa; M C Sollaino; N Giagu; S Barella; S Campus; C Mandas; P Bina; L Perseu; R Galanello
Journal:  Br J Haematol       Date:  2006-11-27       Impact factor: 6.998

5.  Serum erythropoietin and circulating transferrin receptor in thalassemia intermedia patients with heterogeneous genotypes.

Authors:  C Camaschella; S Gonella; R Calabrese; F Vischia; A Roetto; G Graziadei; U Mazza; M D Cappellini
Journal:  Haematologica       Date:  1996 Sep-Oct       Impact factor: 9.941

6.  Splenectomy for children with thalassemia.

Authors:  Ahmed H Al-Salem; Zaki Nasserulla
Journal:  Int Surg       Date:  2002 Oct-Dec

7.  Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia)

Authors:  J Yuan; E Angelucci; G Lucarelli; M Aljurf; L M Snyder; C R Kiefer; L Ma; S L Schrier
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

8.  Iron overload in Chinese patients with hemoglobin H disease.

Authors:  H C Hsu; C K Lin; S H Tsay; E Tse; C H Ho; M P Chow; C H Yung; H W Peng
Journal:  Am J Hematol       Date:  1990-08       Impact factor: 10.047

9.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

10.  Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease.

Authors:  I Papassotiriou; J Traeger-Synodinos; E Kanavakis; M Karagiorga; A Stamoulakatou; C Kattamis
Journal:  J Pediatr Hematol Oncol       Date:  1998 Nov-Dec       Impact factor: 1.289

View more
  4 in total

1.  Phosphatidylserine-exposed red blood cells and ineffective erythropoiesis biomarkers in patients with thalassemia.

Authors:  Siriyakorn Chansai; Supawadee Yamsri; Supan Fucharoen; Goonnapa Fucharoen; Nattiya Teawtrakul
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  Clinical and Biochemical Data of Adult Thalassemia Major patients (TM) with Multiple Endocrine Complications (MEC) versus TM Patients with Normal Endocrine Functions: A long-term Retrospective Study (40 years) in a Tertiary Care Center in Italy.

Authors:  Vincenzo De Sanctis; Heba Elsedfy; Ashraf T Soliman; Ihab Zaki Elhakim; Christos Kattamis; Nada A Soliman; Rania Elalaily
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-12       Impact factor: 2.576

3.  Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study.

Authors:  Hani Ayyash; Mahmoud Sirdah
Journal:  Int J Health Sci (Qassim)       Date:  2018 Nov-Dec

4.  Clinical and hematological features among β-thalassemia major patients in Jazan region: A hospital-based study.

Authors:  Mohammed Mansour Khawaji; Ahmad Ali Hazzazi; Mohssen Hassen Ageeli; Yahya Hassan Mawkili; Abdulrahman Hussain Darbashi; Anwar Mohammed Ali Abo Kathiyah; Rehab Abdalrhman Humedi
Journal:  J Family Med Prim Care       Date:  2020-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.